 Shanta Zimmer
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 13 | 2021 | 610 | 1.130 |
Why?
| | Influenza A Virus, H1N1 Subtype | 8 | 2011 | 147 | 0.970 |
Why?
| | Physician-Patient Relations | 3 | 2016 | 582 | 0.690 |
Why?
| | Physicians, Women | 1 | 2020 | 87 | 0.610 |
Why?
| | Vulnerable Populations | 1 | 2020 | 167 | 0.590 |
Why?
| | Coronavirus Infections | 2 | 2023 | 373 | 0.590 |
Why?
| | Neisseria meningitidis | 3 | 2007 | 25 | 0.570 |
Why?
| | Lymphocyte Antigen 96 | 3 | 2008 | 24 | 0.570 |
Why?
| | Communicable Diseases | 1 | 2020 | 161 | 0.570 |
Why?
| | Internship and Residency | 6 | 2019 | 1180 | 0.520 |
Why?
| | Professional Misconduct | 1 | 2016 | 14 | 0.490 |
Why?
| | Meningitis, Meningococcal | 2 | 2006 | 6 | 0.470 |
Why?
| | Pennsylvania | 8 | 2021 | 131 | 0.470 |
Why?
| | Faculty | 1 | 2016 | 151 | 0.460 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 375 | 0.450 |
Why?
| | Meningococcal Vaccines | 2 | 2006 | 64 | 0.450 |
Why?
| | Curriculum | 4 | 2024 | 1010 | 0.450 |
Why?
| | Internal Medicine | 4 | 2018 | 273 | 0.420 |
Why?
| | Seroepidemiologic Studies | 2 | 2021 | 164 | 0.360 |
Why?
| | Influenza Vaccines | 6 | 2011 | 531 | 0.360 |
Why?
| | Physicians | 3 | 2016 | 929 | 0.340 |
Why?
| | Education, Medical, Graduate | 4 | 2019 | 495 | 0.320 |
Why?
| | Computer Simulation | 9 | 2012 | 997 | 0.320 |
Why?
| | Education, Medical, Undergraduate | 1 | 2012 | 191 | 0.310 |
Why?
| | Toll-Like Receptor 4 | 4 | 2008 | 275 | 0.310 |
Why?
| | Reassortant Viruses | 1 | 2009 | 8 | 0.310 |
Why?
| | Students, Medical | 2 | 2024 | 357 | 0.310 |
Why?
| | Zoonoses | 1 | 2009 | 38 | 0.300 |
Why?
| | Communicable Diseases, Emerging | 1 | 2009 | 40 | 0.300 |
Why?
| | Lipid A | 3 | 2007 | 28 | 0.290 |
Why?
| | Orthomyxoviridae Infections | 1 | 2009 | 68 | 0.290 |
Why?
| | Respiratory Tract Infections | 2 | 2023 | 384 | 0.270 |
Why?
| | Zygomycosis | 1 | 2007 | 6 | 0.270 |
Why?
| | Cyclosporiasis | 1 | 2007 | 1 | 0.270 |
Why?
| | Dermatomycoses | 1 | 2007 | 8 | 0.260 |
Why?
| | Paclitaxel | 1 | 2008 | 237 | 0.260 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2008 | 191 | 0.260 |
Why?
| | Oxazolidinones | 2 | 2004 | 15 | 0.260 |
Why?
| | Sexual and Gender Minorities | 2 | 2022 | 229 | 0.250 |
Why?
| | Acetamides | 2 | 2004 | 37 | 0.250 |
Why?
| | Thiazoles | 1 | 2007 | 127 | 0.250 |
Why?
| | Gram-Positive Bacterial Infections | 2 | 2005 | 69 | 0.250 |
Why?
| | Triazoles | 1 | 2007 | 156 | 0.240 |
Why?
| | Humans | 50 | 2024 | 139073 | 0.240 |
Why?
| | Leadership | 2 | 2020 | 396 | 0.240 |
Why?
| | Fungi | 1 | 2007 | 150 | 0.240 |
Why?
| | Drug Hypersensitivity | 1 | 2007 | 94 | 0.230 |
Why?
| | History, 21st Century | 2 | 2020 | 215 | 0.230 |
Why?
| | Schools | 4 | 2021 | 463 | 0.230 |
Why?
| | History, 20th Century | 2 | 2020 | 327 | 0.220 |
Why?
| | Disease Outbreaks | 5 | 2010 | 417 | 0.220 |
Why?
| | Exploratory Behavior | 1 | 2024 | 91 | 0.210 |
Why?
| | Medical Tourism | 1 | 2023 | 9 | 0.210 |
Why?
| | Coronavirus NL63, Human | 1 | 2023 | 3 | 0.200 |
Why?
| | Coronavirus OC43, Human | 1 | 2023 | 6 | 0.200 |
Why?
| | Coronavirus 229E, Human | 1 | 2023 | 7 | 0.200 |
Why?
| | Enterococcus faecalis | 1 | 2003 | 27 | 0.200 |
Why?
| | Models, Molecular | 1 | 2008 | 1598 | 0.200 |
Why?
| | Sulfonamides | 1 | 2007 | 511 | 0.200 |
Why?
| | Endocarditis, Bacterial | 1 | 2003 | 45 | 0.200 |
Why?
| | Clinical Clerkship | 1 | 2024 | 104 | 0.200 |
Why?
| | Meningitis | 1 | 2023 | 81 | 0.190 |
Why?
| | Models, Economic | 3 | 2012 | 61 | 0.190 |
Why?
| | Pre-Exposure Prophylaxis | 2 | 2022 | 227 | 0.180 |
Why?
| | Mycobacterium abscessus | 1 | 2023 | 118 | 0.180 |
Why?
| | Viruses | 1 | 2023 | 162 | 0.170 |
Why?
| | Emergency Responders | 1 | 2021 | 35 | 0.170 |
Why?
| | Program Evaluation | 3 | 2019 | 913 | 0.160 |
Why?
| | Crowding | 1 | 2020 | 36 | 0.160 |
Why?
| | Awards and Prizes | 1 | 2020 | 72 | 0.160 |
Why?
| | Shoulder | 1 | 2020 | 93 | 0.150 |
Why?
| | Frail Elderly | 1 | 2020 | 130 | 0.150 |
Why?
| | Prisons | 1 | 2020 | 81 | 0.150 |
Why?
| | Surgery Department, Hospital | 1 | 2018 | 22 | 0.140 |
Why?
| | Virus Diseases | 1 | 2021 | 214 | 0.140 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2023 | 364 | 0.140 |
Why?
| | Minority Groups | 1 | 2020 | 274 | 0.140 |
Why?
| | Financing, Organized | 1 | 2018 | 38 | 0.140 |
Why?
| | Nursing Homes | 1 | 2020 | 174 | 0.140 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 740 | 0.140 |
Why?
| | Adult | 18 | 2023 | 38394 | 0.140 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2018 | 130 | 0.140 |
Why?
| | Faculty, Medical | 2 | 2018 | 290 | 0.140 |
Why?
| | Point-of-Care Systems | 2 | 2017 | 182 | 0.130 |
Why?
| | Preceptorship | 1 | 2017 | 67 | 0.130 |
Why?
| | Clinical Competence | 3 | 2024 | 1140 | 0.130 |
Why?
| | Betacoronavirus | 1 | 2020 | 275 | 0.130 |
Why?
| | Urban Population | 1 | 2020 | 482 | 0.130 |
Why?
| | Population Surveillance | 2 | 2011 | 480 | 0.120 |
Why?
| | Occupational Exposure | 1 | 2020 | 341 | 0.120 |
Why?
| | Societies, Medical | 1 | 2020 | 839 | 0.120 |
Why?
| | Anesthesiology | 1 | 2018 | 158 | 0.120 |
Why?
| | Rural Population | 1 | 2020 | 580 | 0.120 |
Why?
| | HIV Infections | 2 | 2022 | 2946 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 311 | 0.120 |
Why?
| | Endotoxins | 2 | 2007 | 220 | 0.120 |
Why?
| | Female | 18 | 2022 | 74078 | 0.120 |
Why?
| | Continuity of Patient Care | 1 | 2017 | 284 | 0.110 |
Why?
| | Cardiology | 1 | 2017 | 277 | 0.110 |
Why?
| | Sexual Behavior | 1 | 2019 | 487 | 0.110 |
Why?
| | Anti-HIV Agents | 1 | 2022 | 837 | 0.110 |
Why?
| | Binding Sites | 2 | 2008 | 1318 | 0.110 |
Why?
| | Antiviral Agents | 2 | 2011 | 766 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2008 | 1361 | 0.110 |
Why?
| | United States | 7 | 2020 | 15065 | 0.110 |
Why?
| | Male | 17 | 2022 | 68330 | 0.100 |
Why?
| | Hand Hygiene | 1 | 2013 | 9 | 0.100 |
Why?
| | Work Schedule Tolerance | 1 | 2013 | 52 | 0.100 |
Why?
| | Macrophage Activation | 2 | 2005 | 200 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2013 | 98 | 0.100 |
Why?
| | Anti-Bacterial Agents | 1 | 2003 | 1812 | 0.100 |
Why?
| | Macrophages | 4 | 2008 | 1545 | 0.100 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2011 | 2144 | 0.090 |
Why?
| | Receptors, Cell Surface | 2 | 2005 | 394 | 0.090 |
Why?
| | Membrane Glycoproteins | 2 | 2005 | 500 | 0.090 |
Why?
| | Patients | 1 | 2013 | 180 | 0.090 |
Why?
| | Patient Admission | 1 | 2013 | 202 | 0.090 |
Why?
| | Social Support | 1 | 2016 | 628 | 0.090 |
Why?
| | Antibodies, Viral | 2 | 2021 | 649 | 0.090 |
Why?
| | Surveys and Questionnaires | 3 | 2021 | 5892 | 0.090 |
Why?
| | Poverty Areas | 1 | 2011 | 40 | 0.090 |
Why?
| | Pandemics | 1 | 2020 | 1650 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2011 | 2369 | 0.090 |
Why?
| | Patient Preference | 1 | 2013 | 197 | 0.090 |
Why?
| | Guanidines | 1 | 2011 | 41 | 0.090 |
Why?
| | Cyclopentanes | 1 | 2011 | 19 | 0.090 |
Why?
| | Aged | 8 | 2020 | 24237 | 0.090 |
Why?
| | Health Care Costs | 2 | 2011 | 418 | 0.080 |
Why?
| | Hemagglutinins | 1 | 2010 | 9 | 0.080 |
Why?
| | Hospitalization | 1 | 2020 | 2224 | 0.080 |
Why?
| | Students | 1 | 2016 | 626 | 0.080 |
Why?
| | Quality Improvement | 1 | 2019 | 1202 | 0.080 |
Why?
| | Clostridium Infections | 1 | 2011 | 72 | 0.080 |
Why?
| | Pneumococcal Infections | 1 | 2011 | 109 | 0.080 |
Why?
| | Quarantine | 1 | 2010 | 31 | 0.080 |
Why?
| | Communication | 1 | 2016 | 932 | 0.080 |
Why?
| | Occupational Health Services | 1 | 2009 | 32 | 0.080 |
Why?
| | Health Care Rationing | 1 | 2010 | 62 | 0.080 |
Why?
| | Influenza A Virus, H2N2 Subtype | 1 | 2009 | 1 | 0.080 |
Why?
| | Staphylococcal Infections | 2 | 2012 | 386 | 0.080 |
Why?
| | Antigenic Variation | 1 | 2009 | 10 | 0.080 |
Why?
| | Seasons | 2 | 2023 | 538 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 237 | 0.080 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 232 | 0.080 |
Why?
| | Antibody Specificity | 1 | 2009 | 187 | 0.080 |
Why?
| | Young Adult | 7 | 2020 | 13344 | 0.070 |
Why?
| | Birds | 1 | 2009 | 97 | 0.070 |
Why?
| | Cross Infection | 1 | 2011 | 250 | 0.070 |
Why?
| | Primary Prevention | 1 | 2010 | 198 | 0.070 |
Why?
| | Child | 9 | 2023 | 21907 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 1889 | 0.070 |
Why?
| | Disease Management | 1 | 2012 | 620 | 0.070 |
Why?
| | Meningitis, Bacterial | 1 | 2008 | 46 | 0.070 |
Why?
| | Child, Preschool | 7 | 2021 | 11142 | 0.070 |
Why?
| | Carbohydrate Conformation | 1 | 2007 | 14 | 0.070 |
Why?
| | Pichia | 1 | 2007 | 20 | 0.070 |
Why?
| | Genome, Viral | 1 | 2009 | 222 | 0.070 |
Why?
| | Protein Structure, Secondary | 1 | 2008 | 373 | 0.070 |
Why?
| | Cyclospora | 1 | 2007 | 1 | 0.070 |
Why?
| | Antiparasitic Agents | 1 | 2007 | 4 | 0.070 |
Why?
| | Cell Line | 3 | 2008 | 2876 | 0.070 |
Why?
| | Nitro Compounds | 1 | 2007 | 6 | 0.070 |
Why?
| | Surface Properties | 1 | 2008 | 411 | 0.070 |
Why?
| | Tubulin | 1 | 2008 | 145 | 0.070 |
Why?
| | Species Specificity | 1 | 2008 | 583 | 0.070 |
Why?
| | Linezolid | 2 | 2004 | 23 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2011 | 444 | 0.060 |
Why?
| | Swine | 1 | 2009 | 802 | 0.060 |
Why?
| | District of Columbia | 3 | 2011 | 33 | 0.060 |
Why?
| | Neonatal Screening | 1 | 2008 | 167 | 0.060 |
Why?
| | Antifungal Agents | 1 | 2007 | 141 | 0.060 |
Why?
| | Chronic Disease | 1 | 2012 | 1802 | 0.060 |
Why?
| | Protein Structure, Tertiary | 1 | 2008 | 864 | 0.060 |
Why?
| | Phylogeny | 1 | 2010 | 1007 | 0.060 |
Why?
| | Vancomycin Resistance | 1 | 2005 | 16 | 0.060 |
Why?
| | Enterococcus | 1 | 2005 | 22 | 0.060 |
Why?
| | Adolescent | 7 | 2022 | 21561 | 0.060 |
Why?
| | Antigens, Differentiation | 1 | 2005 | 81 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 518 | 0.060 |
Why?
| | Transfection | 1 | 2007 | 942 | 0.060 |
Why?
| | Efficiency | 2 | 2019 | 101 | 0.060 |
Why?
| | Vaccines, Conjugate | 1 | 2004 | 64 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2051 | 0.050 |
Why?
| | Receptors, Immunologic | 1 | 2005 | 215 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2005 | 889 | 0.050 |
Why?
| | Middle Aged | 9 | 2021 | 33867 | 0.050 |
Why?
| | Animals | 5 | 2009 | 37352 | 0.050 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2004 | 131 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2004 | 90 | 0.050 |
Why?
| | Health Services Accessibility | 1 | 2011 | 1005 | 0.050 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2008 | 1248 | 0.050 |
Why?
| | Bacteremia | 1 | 2005 | 214 | 0.050 |
Why?
| | Aged, 80 and over | 4 | 2020 | 7699 | 0.050 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2928 | 0.050 |
Why?
| | Models, Statistical | 3 | 2011 | 667 | 0.050 |
Why?
| | Odds Ratio | 2 | 2021 | 1084 | 0.050 |
Why?
| | Protein Binding | 1 | 2008 | 2237 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2004 | 239 | 0.040 |
Why?
| | Infant | 4 | 2012 | 9576 | 0.040 |
Why?
| | Influenza B virus | 1 | 2021 | 44 | 0.040 |
Why?
| | Contact Tracing | 1 | 2021 | 25 | 0.040 |
Why?
| | Monte Carlo Method | 2 | 2011 | 142 | 0.040 |
Why?
| | Absenteeism | 1 | 2021 | 52 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2022 | 193 | 0.040 |
Why?
| | Membrane Cofactor Protein | 2 | 2011 | 14 | 0.040 |
Why?
| | Learning | 1 | 2024 | 420 | 0.040 |
Why?
| | Risk Factors | 3 | 2021 | 10426 | 0.040 |
Why?
| | Ecology | 1 | 2021 | 119 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2007 | 4182 | 0.040 |
Why?
| | Stem Cells | 1 | 2023 | 599 | 0.040 |
Why?
| | Regression Analysis | 1 | 2021 | 1015 | 0.040 |
Why?
| | Temperature | 1 | 2021 | 665 | 0.040 |
Why?
| | Cost-Benefit Analysis | 2 | 2011 | 605 | 0.040 |
Why?
| | Diabetes Mellitus | 1 | 2007 | 1055 | 0.040 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 278 | 0.040 |
Why?
| | Schools, Medical | 1 | 2019 | 152 | 0.030 |
Why?
| | Medication Adherence | 1 | 2022 | 503 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1049 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 174 | 0.030 |
Why?
| | Models, Educational | 1 | 2017 | 94 | 0.030 |
Why?
| | Diagnostic Errors | 1 | 2018 | 174 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2021 | 904 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 5736 | 0.030 |
Why?
| | Respiration, Artificial | 1 | 2020 | 671 | 0.030 |
Why?
| | Mice | 3 | 2008 | 17867 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2089 | 0.030 |
Why?
| | Educational Measurement | 1 | 2018 | 295 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 533 | 0.030 |
Why?
| | Infant, Newborn | 3 | 2012 | 6152 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 871 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 335 | 0.030 |
Why?
| | Toll-Like Receptors | 2 | 2005 | 189 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3276 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 699 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2056 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2388 | 0.020 |
Why?
| | Referral and Consultation | 1 | 2017 | 799 | 0.020 |
Why?
| | Signal Transduction | 1 | 2005 | 5094 | 0.020 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2011 | 35 | 0.020 |
Why?
| | Receptors, Interleukin-1 Type I | 1 | 2011 | 24 | 0.020 |
Why?
| | Acids, Carbocyclic | 1 | 2011 | 1 | 0.020 |
Why?
| | Decision Trees | 1 | 2011 | 87 | 0.020 |
Why?
| | Stochastic Processes | 1 | 2011 | 70 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4532 | 0.020 |
Why?
| | Quality-Adjusted Life Years | 1 | 2011 | 109 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 663 | 0.020 |
Why?
| | Diarrhea | 1 | 2011 | 184 | 0.020 |
Why?
| | Gene Frequency | 1 | 2011 | 504 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2012 | 172 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2011 | 336 | 0.020 |
Why?
| | Mass Vaccination | 1 | 2009 | 18 | 0.020 |
Why?
| | Calibration | 1 | 2010 | 146 | 0.020 |
Why?
| | Cost of Illness | 1 | 2012 | 308 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2011 | 415 | 0.020 |
Why?
| | Attitude to Health | 1 | 2013 | 458 | 0.020 |
Why?
| | Streptococcus pneumoniae | 1 | 2011 | 168 | 0.020 |
Why?
| | Travel | 1 | 2010 | 136 | 0.020 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 141 | 0.020 |
Why?
| | Immunization Programs | 1 | 2011 | 218 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1369 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2022 | 15924 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2011 | 375 | 0.020 |
Why?
| | Workplace | 1 | 2009 | 267 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 366 | 0.020 |
Why?
| | Occupational Health | 1 | 2009 | 204 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2011 | 425 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2011 | 1310 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1873 | 0.020 |
Why?
| | Pilot Projects | 1 | 2011 | 1763 | 0.020 |
Why?
| | Environmental Exposure | 1 | 2010 | 568 | 0.010 |
Why?
| | Kidney Failure, Chronic | 1 | 2011 | 581 | 0.010 |
Why?
| | Gram-Negative Bacteria | 1 | 2005 | 76 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2005 | 270 | 0.010 |
Why?
| | DNA | 1 | 2011 | 1449 | 0.010 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2005 | 105 | 0.010 |
Why?
| | Growth | 1 | 2004 | 52 | 0.010 |
Why?
| | Incidence | 1 | 2011 | 2836 | 0.010 |
Why?
| | Sugar Acids | 1 | 2004 | 3 | 0.010 |
Why?
| | Respiratory Burst | 1 | 2004 | 20 | 0.010 |
Why?
| | U937 Cells | 1 | 2004 | 26 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2008 | 977 | 0.010 |
Why?
| | Antigens, Surface | 1 | 2004 | 153 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1818 | 0.010 |
Why?
| | Toll-Like Receptor 2 | 1 | 2004 | 117 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 10965 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 569 | 0.010 |
Why?
| | Vaccination | 1 | 2011 | 1435 | 0.010 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2005 | 431 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2013 | 5537 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2008 | 3585 | 0.010 |
Why?
| | Nitric Oxide | 1 | 2005 | 895 | 0.010 |
Why?
| | Time Factors | 1 | 2009 | 6885 | 0.010 |
Why?
| | Cytokines | 1 | 2005 | 2084 | 0.010 |
Why?
|
|
Zimmer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|